A profile of the binx health <i>io</i>® molecular point-of-care test for chlamydia and gonorrhea in women and men

Pol, Barbara Van Der; Gaydos, Charlotte A.

doi:10.1080/14737159.2021.1952074

Cited by 16 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ongoing diagnostics research is necessary to develop POCTs for CT and NG that meet more, if not all these criteria. For example, the binx io CT/NG assay is now available on the market and has an analytic time of only thirty minutes [ 106 ], however current cost is likely to be prohibitive to a widescale rollout in LMICs. Importantly, the need for equipment was a barrier to the use of POCTs, and so accurate RDTs are still the most suitable type of test.…”

Section: Discussionmentioning

confidence: 99%

Facilitators and barriers to point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review

et al. 2022

View full text Add to dashboard Cite

Background Sexually transmitted infections (STIs) in low- and middle-income countries (LMICs) are predominantly managed by syndromic management. However, most STIs are asymptomatic. These untreated STIs cause individual morbidity, and lead to high STI prevalences. There is increasing interest in the use of point-of-care tests (POCTs) for STIs in LMICs, which could facilitate same day testing and treatment. To best utilise these tests, we must understand the facilitators and barriers to their implementation. The aim of this review is to explore how point-of-care testing for STIs has been implemented into healthcare systems in LMIC and the facilitators and barriers to doing so. Methods A scoping review was conducted by searching MEDLINE, Embase, Emcare, CINAHL, Scopus, LILACS, the Cochrane Library, and ProQuest Dissertations and Theses for studies published between 1st January 1998 and 5th June 2020. Abstracts and full articles were screened independently by two reviewers. Studies were considered for inclusion if they assessed the acceptability, feasibility, facilitators, or barriers to implementation of point-of-care testing for chlamydia, gonorrhoea, trichomoniasis or syphilis in LMICs. Thematic analysis was used to analyse and present the facilitators and barriers to point-of-care STI testing. Results The literature search revealed 82 articles suitable for inclusion; 44 (53.7%) from sub-Saharan Africa; 21 (25.6%) from Latin American and the Caribbean; 10 (12.2%) from East Asia and the Pacific; 6 (7.3%) from South Asia; and one (1.2%) multi-regional study. Thematic analysis revealed seven overarching themes related to the implementation of POCTs in LMICs, namely (i) Ideal test characteristics, (ii) Client factors, (iii) Healthcare provision factors, (iv) Policy, infrastructure and health system factors, (v) Training, audit, and feedback, (vi) Reaching new testing environments, and (vii) Dual testing. Conclusion Implementation of POCTs in LMICs is complex, with many of the barriers due to wider health system weakness. In addition to pressing for broader structural change to facilitate basic healthcare delivery, these themes may also be used as a basis on which to develop future interventions. The literature was heavily skewed towards syphilis testing, and so more research needs to be conducted assessing chlamydia, gonorrhoea, and trichomoniasis testing, as well as home or self-testing.

show abstract

Section: Discussionmentioning

confidence: 99%

Facilitators and barriers to point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…34 The SD Bioline HIV/Syphilis Duo test, a dual syphilis and HIV rapid screening test, has been validated in multiple African settings, 35,36 but is not yet widely integrated into HIV testing programs. Over the last decade, there has been major advancement in the development of POC STI diagnostics for other curable STIs including the OSOM lateral flow test for trichomonas, 37 the Binx health io test for gonorrhea and chlamydia, 38 and the Visby test, for gonorrhea, chlamydia and trichomonas 39 . While these tests theoretically could lead to more timely and improved STI care in sub-Saharan Africa, their effectiveness and implementation still needs rigorous evaluation in low resource settings and cost remains a major barrier to rollout.…”

Section: Discussionmentioning

confidence: 99%

The HIV and STI syndemic following mass scale-up of combination HIV interventions in Uganda: a population-based cross-sectional study

Grabowski

Mpagazi

Kiboneka

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Combination HIV interventions (CHIs) have led to significant declines in HIV incidence in sub-Saharan Africa; however, population-level data on non-HIV sexually transmitted infection (STI) burden in the context of CHIs are rare. We aimed to assess STI burden in Uganda following mass scale-up of CHIs, including universal HIV treatment. Methods: The Sexually Transmitted Infection Prevalence Study (STIPS) was a cross-sectional study nested within the Rakai Community Cohort Study (RCCS), a population-based cohort among inland agrarian and Lake Victoria fishing populations in southern Uganda. STIPS enrolled consenting participants, 18-49 years, between May and October 2019 and measured prevalence of Chlamydia trachomatis (chlamydia), Neisseria gonorrhoeae (gonorrhea), Trichomonas vaginalis (trichomonas), syphilis, and herpes simplex virus type 2 (HSV-2). Findings: STIPS enrolled 1,825 participants, including 965 women (53%), of whom 9% (n=107) were pregnant. Overall, there was 9.8% prevalence of chlamydia (95%CI:8.5-11%), 6.7% gonorrhea (95%CI:5.7-8.0%), and 11% trichomonas (95%CI:9.5-12%). In the fishing population, syphilis reactivity was 24% (95%CI:22-27%), with 9.4% (95%CI:7.7-11%) having high titer (RPR ≥1:8) infection, including 17% (95%CI:12-24%) of HIV-positive men. Prevalence of ≥1 curable STI (chlamydia, gonorrhea, trichomonas, or high titer syphilis) was 44% higher among HIV-positive persons (adjusted prevalence risk ratio [adjPRR]=1.44,95%CI:1.22-1.71), with no differences by HIV treatment status. HIV-positive pregnant women were more likely than HIV-negative pregnant women to have a curable STI (adjPRR=1.87, 95%CI: 1.08-3.23). Interpretation: STI burden remains extremely high in Uganda, particularly among HIV-positive persons. There is an urgent need to integrate STI diagnostic testing and treatment with HIV services in African settings.

show abstract

“…Finally, the io® CT/NG assay and its performance characteristics were recently profiled by Van Der Pol and Gaydos. 64…”

Section: Binx Iomentioning

confidence: 99%

Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men

Cited by 16 publications

References 40 publications

Facilitators and barriers to point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review

Facilitators and barriers to point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review

The HIV and STI syndemic following mass scale-up of combination HIV interventions in Uganda: a population-based cross-sectional study

Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections

Contact Info

Product

Resources

About